Search Results for 'Phase II'

Search For:
Refine by Dates:
From: To:
Refine By Content:

Contract Service Directory Companies

View All Buyers Guide Companies »

Contract Service Directory Categories

View All Categories »

  • Capsugel Expands DPI Delivery to Phase II Trials

    May 5, 2015
    To add commercial spray-drying capacity for inhalation technologies to treat
a wider range of diseases

  • Phase II

    February 27, 2012
    Following initial safety (Phase I) testing, a drug is tested for efficacy, typically in blind, randomized trials, in which a control group receives a placebo. Phase II testing may last from several months to two years. Phase II trials involve 100-300…

  • GSK, Theravance Begin Phase II COPD Trial

    December 22, 2010
    GlaxoSmithKline and Theravance have initiated a Phase IIb study to evaluate the efficacy and safety of GSK961081 (‘081), in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

  • Peregrine's Bavituximab Shows Promise in Phase II

    May 27, 2010
    Peregrine Pharmaceuticals achieved positive results from a Phase II trial evaluating bavituximab in combination with paclitaxel and carboplatin chemotherapy in patients with advanced breast cancer.

  • Revotar Gets Positive Phase II Results in COPD

    May 18, 2010
    Revotar Biopharmaceuticals achieved positive results in Phase IIa Ozone Study with Bimosiamose for COPD.

  • Neotropix Initiates Phase II Lung Cancer Trial

    May 14, 2010
    Neotropix began enrolling patients in a Phase II trial to assess the efficacy of the novel oncolytic virus, NTX-010, in patients with extensive stage small cell lung cancer (SCLC).

  • Synta Initiates Phase II GIST Trial

    December 28, 2009
    Synta Pharmaceuticals Corp. has initiated a Phase II trial of STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST).

  • MedImmune Moves Asthma MAb to Phase II

    December 4, 2008
    MedImmune has initiated a Phase II clinical trial in patients with chronic asthma to determine the safety of subcutaneous dosing of MEDI-563 a humanized monoclonal antibody (MAb) that targets the interleukin-5 receptor (IL-5R). Preclinical data sugge…

  • Kendle Acquires Charles River Labs' Phase II-IV Services

    May 10, 2006
    Kendle will acquire the Phase II-IV Clinical Services business of Charles River Laboratories International, Inc. for approximately $215 million in cash. The move will strengthen Kendle's position in the clinical development industry, adding therapeut…